Notes
including hallucinations, agitation, hostility, irritability, depression, disorientation, anxiety, memory impairment, restlessness, cognitive impairment, insomnia, dream abnormalities, suicidal ideation and behaviour, suicide, and tremor.
PubMed, EMBASE, MEDLINE and Cochrane Library
including completed suicide, suicide attempt, suicidal ideation, and self-harm either presented separately or as a combined outcome.
including hallucinations, agitation, hostility, irritability, depression, disorientation, anxiety, memory impairment, restlessness, cognitive impairment, insomnia, dream abnormalities, suicidal ideation and behaviour, suicide, and tremor.
Reference
Law SWY, et al. Neuropsychiatric Events Associated with Leukotriene-Modifying Agents: A Systematic Review. Drug Safety : [13 pages], 26 Oct 2017. Available from: URL: http://dx.doi.org/10.1007/s40264-017-0607-1
Rights and permissions
About this article
Cite this article
No clear link between LTMAs and neuropsychiatric AEs. Reactions Weekly 1676, 8 (2017). https://doi.org/10.1007/s40278-017-37996-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-017-37996-3